FDA continues to take steps to fulfill its commitment to strengthen and modernize the 510(k) medical device program

FDA publishes draft guidance documents to provide device-specific performance criteria for the Safety and Performance Based Pathway

News provided by

U.S. Food and Drug Administration

Sep 19, 2019, 11:17 ET

SILVER SPRING, Md., Sept. 19, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today announced that, as a first step toward implementation of the recently established Safety and Performance Based Pathway for medical devices, the agency is issuing draft guidances outlining the recommended premarket performance criteria and testing methodologies for four specific types of devices. These are anticipated to be the first device types eligible for the new, voluntary premarket notification pathway to market devices, which was first announced in 2018 and finalized through guidance earlier this year.

The initial device types being considered for eligibility for the Safety and Performance Based Pathway under the draft guidances issued today include:

"One of our goals with the Safety and Performance Based Pathway is to ensure that the 510(k) program is keeping pace with the important innovations we're seeing in device development. This new pathway reflects our focus on advancing new products that are safer and more effective," said Jeff Shuren, M.D., director of the FDA's Center for Devices and Radiological Health. "This new option for 510(k) clearance of certain well-understood device types will allow manufacturers to use objective performance criteria—established or recognized by the FDA—to demonstrate substantial equivalence of their new products or superior performance to those already legally on the market. For example, if a manufacturer wants to market a new spinal plating system that falls within the scope of the guidance, with this new pathway, they would submit a 510(k) demonstrating that the safety and performance characteristics of their device are consistent with the new FDA-identified criteria. They would not need to provide a side-by-side performance assessment with a predicate device. The major benefit is that the pathway will benchmark modern technology against modern standards while, at the same time, offering a potentially more efficient way to demonstrate a new device is substantially equivalent to devices already on the market. This ensures patients have timely access to beneficial products. This new approach may also drive greater market competition to develop safer, more effective devices by providing the opportunity to demonstrate superior performance to the FDA-established benchmarks."

The Safety and Performance Based Pathway provides an option to medical device manufacturers seeking premarket clearance of certain, well-understood device types. With a premarket notification, also known as a 510(k), a manufacturer demonstrates that its product has the same intended use and the same technological characteristics as a device already on the market (known as a predicate device); if the product has different technological characteristics, the manufacturer must demonstrate that its product is at least as safe and effective as, and does not raise different questions of safety and effectiveness than, the predicate device. Manufacturers often conduct direct comparison testing to demonstrate that a new device is as safe and effective as the predicate device. In some cases, predicates may be older and may not reflect modern technologies embedded in new devices. In the new pathway, the safety and performance characteristics of new devices are evaluated against a set of FDA-identified objective and transparent metrics consistent with the safety and performance characteristics of modern predicates. Devices being reviewed and cleared under this new pathway must still meet regulatory requirements for safety and effectiveness; however, the FDA expects this pathway to promote a competitive marketplace for developing even safer, more effective technologies, ultimately giving patients timely access to more beneficial medical devices.

These first four device-specific guidances were chosen because for these device types, the agency had already worked to develop performance criteria and/or FDA-recognized consensus standards exist for the performance of these devices. The FDA is soliciting public feedback on these guidances, which will assist in the finalization of the initial device-specific guidances and also aid in expansion of the pathway to other types of medical devices in the coming months.

In addition to publishing these four draft guidances, the FDA is also updating the Safety and Performance Based pathway guidance issued in February 2019 to further clarify the information the FDA will review in a 510(k) using the Safety and Performance Based Pathway.

In February 2019, the FDA announced the framework for the Safety and Performance Based Pathway through final guidance. It is optional and will not change existing review processes.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Alison Hunt, 240-402-0764, [email protected]
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration